Olson Eric R 4
4 · Syros Pharmaceuticals, Inc. · Filed Aug 19, 2020
Insider Transaction Report
Form 4
Olson Eric R
Chief Scientific Officer
Transactions
- Sale
Common Stock
2020-08-18$13.00/sh−10,787$140,231→ 0 total - Exercise/Conversion
Common Stock
2020-08-17$1.01/sh+4,963$5,013→ 4,963 total - Exercise/Conversion
Stock Option (right to buy)
2020-08-17−4,963→ 105,112 totalExercise: $1.01Exp: 2023-05-22→ Common Stock (4,963 underlying) - Exercise/Conversion
Common Stock
2020-08-18$1.01/sh+10,787$10,895→ 10,787 total - Sale
Common Stock
2020-08-17$13.00/sh−4,963$64,519→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2020-08-18−10,787→ 94,325 totalExercise: $1.01Exp: 2023-05-22→ Common Stock (10,787 underlying)
Footnotes (2)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]This option is fully vested.